BMS Aims To Unseat Otezla In Psoriasis With US FDA-Approved Sotyktu
TYK2 Inhibitor Grows Bristol’s Immunology Franchise
Chief commercialization officer Chris Boerner said BMS plans to replace Otezla as the oral standard of care for moderate-to-severe psoriasis with Sotyktu (deucravacitinib); its list price is about 40% higher than Amgen’s product.
You may also be interested in...
Ventyx’s TYK2 inhibitor met primary and secondary endpoints in a Phase II psoriasis trial, but the biotech determined the data are not competitive in a class led by Bristol’s Sotyktu.
The partners’ orally administered IL-23R inhibitor met all primary and secondary endpoints in a Phase IIb plaque psoriasis trial, justifying advancement to Phase III even though its efficacy fell short of available injectables according to cross-trial comparisons.
Bristol Myers Squibb brought the last of nine new drugs to market last year – all needed to help it overcome three big losses of exclusivity this decade – so the focus this year is commercial execution.